Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.
Int J Biol Macromol
; 163: 1-8, 2020 Nov 15.
Article
in English
| MEDLINE | ID: covidwho-620551
ABSTRACT
The current pandemic of 2019 novel coronavirus disease (COVID-19) caused by a novel virus strain, 2019-nCoV/SARS-CoV-2 have posed a serious threat to global public health and economy. It is largely unknown how the human immune system responds to this infection. A better understanding of the immune response to SARS-CoV-2 will be important to develop therapeutics against COVID-19. Here, we have used transcriptomic profile of human alveolar adenocarcinoma cells (A549) infected with SARS-CoV-2 and employed a network biology approach to generate human-virus interactome. Network topological analysis discovers 15 SARS-CoV-2 targets, which belongs to a subset of interferon (IFN) stimulated genes (ISGs). These ISGs (IFIT1, IFITM1, IRF7, ISG15, MX1, and OAS2) can be considered as potential candidates for drug targets in the treatments of COVID-19. We have identified significant interaction between ISGs and TLR3 agonists, like poly I C, and imiquimod, and suggests that TLR3 agonists can be considered as a potential drug for drug repurposing in COVID-19. Our network centric analysis suggests that moderating the innate immune response is a valuable approach to target COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
ELAV-Like Protein 2
/
Betacoronavirus
Limits:
Humans
Language:
English
Journal:
Int J Biol Macromol
Year:
2020
Document Type:
Article
Affiliation country:
J.ijbiomac.2020.06.228
Similar
MEDLINE
...
LILACS
LIS